<- Go Home
BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines. The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Market Cap
AUD 213.9M
Volume
360.6K
Cash and Equivalents
AUD 7.6M
EBITDA
AUD 10.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 19.7M
Profit Margin
41.05%
52 Week High
AUD 1.10
52 Week Low
AUD 0.33
Dividend
N/A
Price / Book Value
10.26
Price / Earnings
23.43
Price / Tangible Book Value
10.43
Enterprise Value
AUD 211.6M
Enterprise Value / EBITDA
19.90
Operating Income
AUD 9.9M
Return on Equity
66.14%
Return on Assets
24.99
Cash and Short Term Investments
AUD 7.6M
Debt
AUD 5.4M
Equity
AUD 20.2M
Revenue
AUD 48.0M
Unlevered FCF
-AUD 2.3M
Sector
Life Sciences Tools and Services
Category
N/A